Globeflex Capital L P Has $32.47 Million Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Globeflex Capital L P boosted its position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 203.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 975,151 shares of the biotechnology company's stock after purchasing an additional 654,200 shares during the quarter. Exelixis comprises 2.8% of Globeflex Capital L P's holdings, making the stock its 6th biggest position. Globeflex Capital L P owned approximately 0.34% of Exelixis worth $32,473,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of EXEL. Seizert Capital Partners LLC raised its position in shares of Exelixis by 8.0% during the 3rd quarter. Seizert Capital Partners LLC now owns 469,940 shares of the biotechnology company's stock worth $12,195,000 after buying an additional 34,875 shares in the last quarter. Tri Ri Asset Management Corp bought a new stake in shares of Exelixis during the 3rd quarter worth about $4,396,000. Blue Trust Inc. raised its position in shares of Exelixis by 134.7% during the 4th quarter. Blue Trust Inc. now owns 14,302 shares of the biotechnology company's stock worth $476,000 after buying an additional 8,208 shares in the last quarter. Navellier & Associates Inc. bought a new stake in shares of Exelixis during the 3rd quarter worth about $573,000. Finally, Intech Investment Management LLC raised its position in shares of Exelixis by 48.2% during the 3rd quarter. Intech Investment Management LLC now owns 232,041 shares of the biotechnology company's stock worth $6,021,000 after buying an additional 75,489 shares in the last quarter. 85.27% of the stock is currently owned by institutional investors.

Remove Ads

Analysts Set New Price Targets

A number of analysts have commented on EXEL shares. Citigroup boosted their price target on shares of Exelixis from $38.00 to $45.00 and gave the stock a "buy" rating in a research report on Wednesday, February 12th. Stifel Nicolaus boosted their price target on shares of Exelixis from $30.00 to $36.00 and gave the stock a "hold" rating in a research report on Wednesday, February 12th. BMO Capital Markets downgraded shares of Exelixis from an "outperform" rating to a "market perform" rating and boosted their price target for the stock from $36.00 to $40.00 in a research report on Friday, December 20th. JMP Securities reiterated a "market outperform" rating and issued a $41.00 target price on shares of Exelixis in a report on Thursday, January 23rd. Finally, Wells Fargo & Company downgraded shares of Exelixis from an "overweight" rating to an "equal weight" rating and set a $36.00 target price on the stock. in a report on Monday, February 24th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $37.59.

Insider Buying and Selling at Exelixis

In other Exelixis news, Director Bob Oliver sold 18,647 shares of the stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $37.25, for a total value of $694,600.75. Following the completion of the sale, the director now directly owns 33,514 shares of the company's stock, valued at $1,248,396.50. This represents a 35.75 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Patrick J. Haley sold 52,636 shares of the stock in a transaction on Monday, February 24th. The shares were sold at an average price of $36.98, for a total transaction of $1,946,479.28. Following the completion of the sale, the executive vice president now directly owns 303,310 shares of the company's stock, valued at approximately $11,216,403.80. This trade represents a 14.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 140,343 shares of company stock valued at $5,177,234 in the last ninety days. Company insiders own 2.85% of the company's stock.

Exelixis Stock Down 1.8 %

Exelixis stock traded down $0.66 during mid-day trading on Tuesday, reaching $36.36. The company had a trading volume of 1,934,008 shares, compared to its average volume of 2,069,508. Exelixis, Inc. has a 52 week low of $20.14 and a 52 week high of $40.02. The company has a 50 day moving average of $35.48 and a 200-day moving average of $32.68. The firm has a market cap of $10.18 billion, a price-to-earnings ratio of 20.54, a PEG ratio of 1.13 and a beta of 0.57.

Exelixis (NASDAQ:EXEL - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing analysts' consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. On average, analysts predict that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.